Skip to content

Author

De-Mei Feng

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Nov 2026

Comparative efficacy and safety of first-line therapies for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: a systematic review and network meta-analysis.

BACKGROUND First-line regimens incorporating immune checkpoint inhibitors (ICIs), adoptive cell therapy (ACT), and targeted agents have expanded treatment options for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma, but their comparative efficacy and safety remain uncertain. METHODS We sear...

Wen-Wei Yang, Qi Cao, B. Cao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.